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Background: Dopamine agonists (DA) are the first-choice drug for treatment of the early stage of Parkinson’s
disease (PD) in subjects younger than 70 years. Recently, a number of third generation DA have been marketed,
including transdermal patch of rotigotine and extended release oral formulation of ropinirole and pramipexole.
We investigated the impact of third generation DA on management of the early stage of PD in an outpatient
service for Movement Disorders in Italy.
Methods: Two 12-month observation periods were selected (January - December, 2007, and January - December,
2011) as representative for prescription of immediate and extended release formulations of DA respectively. Within
each period, PD patients were divided into subgroups according to age (<65 years; 65–75 years; >75 years) or
functional requirement (high; moderate; low). For each period, the number of subjects receiving monotherapy with
DA, monotherapy with levodopa (LD), or combined DA/LD therapy and the relative doses were calculated. The
severity of parkinsonian motor symptoms was calculated by means of the Unified Parkinson’s Disease Rating Scale
part III (UPDRS-III) score. The frequency and severity of side-effects leading to discontinuation or reduction of DA
drugs at each time point were also calculated.
Results: We found a significant reduction of daily LD dose (both as mono- and combined therapy) between the
second and the first observation period. There was also a significant increase of monotherapy with DA and
corresponding reduction of monotherapy with LD in patients aged 65–75 years, as well as in PD patients with
moderate functional requirements. A significant reduction of frequency of side-effects was measured with extended
release DA as compared to immediate release formulations. There were no significant differences of the UPDRS-III
scores between the 2 observation periods in any subgroup.
Conclusions: Our results suggest that extended release DA might optimize therapeutic management of the early
stages of PD even in patients older than 70 years of age.
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Dopamine agonists (DAs) are the first-choice drugs for
treatment of the early stage of Parkinson’s disease (PD) in
patients younger than 70 years of age [1]. Several pharma-
cokinetic and pharmacodynamic properties of DAs [2], in-
cluding the lack of competition with dietary amino acids
upon crossing of intestinal and blood–brain barrier, the
relatively long striatal half-life, the lack of metabolism and
the direct action at postsynaptic dopamine receptors, con-
tribute to their therapeutic efficacy with reduced risk of
motor complications (fluctuations and dyskinesia) com-
pared to levodopa (LD) [3]. Despite these potential advan-
tages, administration of DAs to PD patients is frequently
limited by peripheral (cardiovascular and/or gastrointes-
tinal) or central (neuropsychiatric and/or cognitive) side
effects [4].
In the past several years, a number of third-generation
DAs have been marketed, including a transdermal formu-
lation of rotigotine (RT) and extended-release oral formu-
lations of pramipexole (PP) and ropinirole (RP). These
nonergolinic DAs enable continuous stimulation of dopa-
mine receptors that more closely resembles physiological
dopaminergic transmission in the basal ganglia [5]. Trans-
dermal RT is efficacious in early stages of PD [6], and
extended-release PP and RP show similar therapeutic
efficacy as immediate-release formulations [7,8] and re-
duction of peak-dose side effects [7-9]. Moreover, the
once-daily administration regimen improves adherence to
the treatment schedule [10]. Taken together, these features
suggest that extended-release formulations may increase
utilization of DAs in PD patients and thus contribute to
further sparing of LD use.
In the present study, we retrospectively investigated the
impact of third-generation DAs on prescribing patterns in
the early stages of PD by collecting data from patients re-
ferred to our Movement Disorder Outpatient Service dur-
ing two periods of time, before and after marketing of
extended-release DAs.
Methods
We conducted a retrospective study of PD patients
recruited sequentially during scheduled visits at the
Outpatient Service for Movement Disorders, Mental Health
and Sensory Organs Department, Sant’Andrea Hospital,
Sapienza University of Rome. In all patients, the PD diagno-
sis was made according to international guidelines, includ-
ing sustained response to dopaminergic medications [11].
Two 12-month periods were selected (1 January 2007
through 31 December 2007 and 1 January 2011 through 31
December 2011) as representative for prescription of
immediate- and extended-release formulations of DAs, re-
spectively. The protocol was approved by the Ethical
Committee of the "Fondazione Santa Lucia IRCCS" and
each subject signed an informed consent at enrollment.The inclusion criteria were (1) Mini Mental State
Examination score ≥27; (2) Hoehn and Yahr (H&Y)
scale stage ≤2 throughout each observation period;
(3) Unified Parkinson’s Disease Rating Scale part III
(UPDRS-III) score ≤30; (4) lack of motor and/or non-
motor fluctuations throughout the observation period,
investigated by the clinical interview based on the items
in the nine-item Wearing-off Questionnaire [12]; and
(5) at least two visits during each observation period.
The exclusion criteria were (1) major medical illnesses
that may have interfered with antiparkinsonian therapy
choice; (2) comorbidity with major psychiatric disorders;
(3) history of alcoholism or drug dependence or abuse;
(4) neuroradiological (computed tomography or mag-
netic resonance imaging scan) evidence of significant
focal abnormalities; and (5) enrollment in clinical
pharmacological trials.
For each participant, the pharmacological therapy used
(drugs, formulation and daily doses) at the last visit of
each 12-month period was taken as representative of the
period itself. Within each 12-month period, eligible pa-
tients were divided into three subgroups according to
their age (<65 years, between 65 and 75 years and >75
years) and three other subgroups according to their
functional requirements (high functional requirement,
defined as still at work or involved in regular daily activ-
ities; moderate functional requirement, defined as being
retired but with regular interests and/or occupations;
and low functional requirement, defined as retirement
alone). For each subgroup, we calculated the number of
patients receiving monotherapy with DAs, monotherapy
with LD or combined DA-LD therapy and the relative
doses. For DA drugs, the following conversion parame-
ters were applied to calculate LD equivalents: 100 mg of
LD = 1 mg of PP = 5 mg of RP = 5 mg RT [7,13]. In the
case of combined therapy, the total daily LD equivalent
was calculated by adding daily LD (in milligrams) to
daily LD equivalents due to DA drugs. Within each 12-
month period, the number of patients experiencing side
effects that forced modification of drug therapy was also
calculated.
Comparisons of continuous variables (sociodemographic
features and daily doses of dopamine replacement therapy)
were analyzed using a two-tailed, unpaired Student’s t-test.
As to categorical variables (presence or absence of DAs
and presence or absence of significant side effects), the χ2
test was applied to analyze differences between the two
periods of investigation.
Results
As shown in Table 1, the two groups did not differ with
regard to age, sex, disease stage measured by the H&Y
scale and severity of parkinsonian symptoms measured
by the UPDRS-III scale. There were no intersubgroup
Table 1 Demographics and clinical features of the enrolled patients a
Demographics and clinical features Year 2007 2011
N (males) 56 (32) 72 (38)
Age, years (mean ± SD) 66 ± 10 69 ± 9
Disease duration, years (mean ± SD) 3.5 ± 1.8 4.6 ± 1.4
Hoehn and Yahr stage (mean ± SD) 1.8 ± 0.4 1.9 ± 0.3
UPDRS-III score (mean ± SD) 20.8 ± 6.1 20.5 ± 6.5
Age <65 years, n (%) 20 (35%) 23 (32%)
Age <65 years, UPDRS-III score (mean ± SD) 19.7 ± 3.9 19.3 ± 5.1
Age between 65 and 75 years, N (%) 30 (54%) 31 (43%)
Age between 65 and 75 years, UPDRS-III score (mean ± SD) 20.1 ± 6.7 21.0 ± 5.9
Age >75 years, n (%) 6 (11%) 18 (25%)
Age >75 years, UPDRS-III score (mean ± SD) 23.9 ± 5.1 23.5 ± 4.6
High functional requirement, n (%) 18 (32%) 24 (33%)
High functional requirement, UPDRS-III score (mean ± SD) 20.2 ± 6.8 20.9 ± 5.9
Moderate functional requirement, n (%) 20 (36%) 19 (26%)
Moderate functional requirement, UPDRS-III score (mean ± SD) 22.1 ± 5.2 21.9 ± 4.8
Low functional requirements, n (%) 18 (32%) 29 (40%)
Low functional requirement, UPDRS-III score (mean ± SD) 24.1 ± 5.2 24.4 ± 4.9
Daily LD, monotherapy, mg (mean ± SD) 328 ± 67 267 ± 62b
Daily DA equivalents, monotherapy, mg (mean ± SD) 237 ± 74 277 ± 62
Daily total LD equivalents, combined therapy, mg (mean ± SD) 483 ± 133 440 ± 111
Daily DA equivalents, combined therapy, mg (mean ± SD) 161 ± 80 177 ± 78
Daily LD, combined therapy, mg (mean ± SD) 330 ± 72 263 ± 61b
Side effects forcing reduction/withdrawal of DA therapy, n (%) 7/37 (18.9%) 7/57 (12.3%)c
aDA, dopamine agonist; LD, levodopa; UPDRS-III, Unified Parkinson’s Disease Rating Scale part III. bP < 0.01 different from 2007 by two-tailed, unpaired Student’s t-
test. cP < 0.01 different from 2007 by χ2 test. See Methods Section for details.
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servation periods (Table 1). As mentioned in the Methods
Section, patients did not experience motor fluctuations
and/or dyskinesia. There were no patients receiving
controlled-release LD and/or amantadine. At each obser-
vation period, ten patients were taking rasagiline (1 mg/
day). In accordance with the current international guide-
lines for therapy in the early stages of PD [1], no patients
were treated with deep brain stimulation.
In the whole patient population, there was a significant
reduction in the daily LD dose between the second and
the first periods of observation (267 ± 62 mg vs. 328 ±
67 mg for patients on monotherapy with LD; 263 ± 61 mg
vs. 330 ± 72 mg for patients on combined therapy with LD
and DA) (Table 1). Moreover, in 2007, the DA dose was in-
creased in seven patients (19%) and reduced in six patients
(15%). Conversely, in 2011, DA dose was increased in ten
patients (18%) and was decreased in six patients (10%).
Analysis of age-related subgroups indicated the signifi-
cant increase of monotherapy with DAs (45% vs. 14%) and
reduction of monotherapy with LD (6% vs. 37%) in pa-
tients aged between 65 and 75 years between the secondand the first observation period (Table 2). In this subgroup
of patients, there was also a significant increase of dosage
of DAs, measured as daily LD equivalents (314 ± 53 mg vs.
250 ± 57 mg) (Table 2).
We found a significant increase in monotherapy with
DAs (53% vs. 25%) and a significant reduction in mono-
therapy with LD (10% vs. 35%) between the second and
first observation periods among patients with moderate
functional requirements (Table 3). In this subgroup, the
daily dose of DAs, expressed as LD equivalents, were
significantly higher in 2011 (325 ± 33 mg) than in 2007
(250 ± 25 mg) (Table 3).
In 2007, moderate to severe side effects were recorded
in 7 (18.9%) of 37 patients treated with DAs (monother-
apy or combined therapy) (Table 1). These side effects
included daytime sleepiness (n = 3), visual hallucinations
(n = 2), impulse control disorder (ICD) (n = 1) and cogni-
tive impairment (n = 1). In two of these cases, the sever-
ity of side effects forced withdrawal of DA therapy. In
the remaining five cases, adverse side effect symptoms
were controlled by reducing the DA dose. Side effects
were detected in patients younger than age 65 (n = 2)
Table 2 Distribution of dopamine replacement therapy according to patient agea
Patient age Therapy 2007 Year 2011
Age <65 years DA monotherapy, n (%) 10 (50%) 14 (61%)
Daily LD equivalents, mg (mean ± SD) 245 ± 52 281 ± 48
LD monotherapy, n (%) 3 (15%) 2 (9%)
Daily mg (mean ± SD) 274 ± 29 275 ± 15
DA + LD combined therapy, n (%) 7 (35%) 7 (30%)
Total daily LD equivalents, mg (mean ± SD) 385 ± 62 388 ± 70
Age between 65 and 75 years DA monotherapy, n (%) 4 (14%) 14 (45%)b
Daily LD equivalents, mg (mean ± SD) 250 ± 57 314 ± 53b
LD monotherapy, n (%) 11 (37%) 2 (6%)b
Daily dose, mg (mean ± SD) 325 ± 50 350 ± 25
DA + LD combined therapy, n (%) 14 (47%) 15 (49%)
Total daily LD equivalents, mg (mean ± SD) 425 ± 40 415 ± 54
Age >75 years DA monotherapy, n (%) 0 (0%) 1 (6%)
Daily LD equivalents, mg (mean ± SD) 250 ± 0
LD monotherapy, n (%) 4 (67%) 11 (61%)
Daily dose, mg (mean ± SD) 465 ± 28 450 ± 20
DA + LD combined therapy, n (%) 2 (33%) 6 (33%)
Total daily LD equivalents, mg (mean ± SD) 525 ± 25 530 ± 22
aDA, dopamine agonist; LD, levodopa. bP < 0.01 compared with 2007 by χ2 statistic or unpaired Student’s t-test statistic. See Methods Section for details.
Table 3 Distribution of dopamine replacement therapy according to patients’ functional requirementsa
Function level Therapy 2007 2011
High DA monotherapy, n (%) 6 (33%) 14 (59%)b
Daily LD equivalents, mg (mean ± SD) 350 ± 57 335 ± 57
LD monotherapy, n (%) 3 (17%) 2 (8%)
Daily dose, mg (mean ± SD) 315 ± 33 325 ± 15
DA + LD combined therapy, n (%) 9 (50%) 8 (33%)
Total daily LD equivalents, mg (mean ± SD) 400 ± 52 415 ± 35
Moderate DA monotherapy, n (%) 5 (25%) 10 (53%)b
Daily LD equivalents, mg (mean ± SD) 250 ± 25 325 ± 33b
LD monotherapy, n (%) 7 (35%) 2 (10%)b
Daily dose, mg (mean ± SD) 280 ± 25 275 ± 12
DA + LD combined therapy, n (%) 8 (40%) 7 (37%)
Total daily LD equivalents, mg (mean ± SD) 324 ± 34 330 ± 35
Low DA monotherapy, n (%) 3 (17%) 4 (14%)
Daily LD equivalents, mg (mean ± SD) 255 ± 15 261 ± 27
LD monotherapy, n (%) 9 (50%) 12 (41%)
Daily dose, mg (mean ± SD) 250 ± 25 230 ± 32
DA + LD combined therapy, n (%) 6 (33%) 13 (45%)
Daily LD equivalents, mg (mean ± SD) 289 ± 21 277 ± 27
aDA, dopamine agonist; LD, levodopa. bP < 0.01 compared with 2007 by χ2 test or unpaired Student’s t-test. See Methods Section for details.
Pellicano et al. European Journal of Medical Research 2013, 18:60 Page 4 of 6
http://www.eurjmedres.com/content/18/1/60
Pellicano et al. European Journal of Medical Research 2013, 18:60 Page 5 of 6
http://www.eurjmedres.com/content/18/1/60and those between 65 and 75 years of age (n = 5). Con-
versely, in 2011, 7 (12.3%) of 57 patients receiving ther-
apy with DAs experienced moderate to severe side
effects (Table 1), including daytime sleepiness (n = 3),
ICD (n = 3) and visual hallucinations (n = 1). In only one
case, the severity of the side effect prompted us to sus-
pend DAs. In the remaining cases, adverse symptoms
were controlled by reducing doses of DAs. Side effects
were reported in one patient aged younger than 65 years
of age, in five between 65 and 75 years of age and in one
patient older than age 75 years. There was a 35% reduc-
tion in the occurrence of side effects in 2011 compared
to 2007 (P < 0.01) (Table 1).
Discussion
We carried out this retrospective, observational study of a
homogeneous cohort of patients (drawn from patients re-
ferred to our Outpatient Service for Movement Disorders)
to evaluate the impact of introduction of extended release
DAs on prescription patterns in the early, uncomplicated,
stages of PD. We are aware of several limitations of this
study, including the small sample size and the lack of data
on therapeutic adherence and treatment satisfaction among
our patients. However, the very similar demographic and
clinical features of the two populations enrolled allowed us
to identify significant differences that might have an impact
on therapeutic management of patients in the early stages
of PD.
The results show that introduction of extended-release
DAs was accompanied by significant reductions in daily
LD doses (Table 1) and a decrease in side effects that
would have required a reduced dose or withdrawal of DA
drugs (Table 1). The prevalence of moderate to severe side
effects associated with extended-release DAs in our pa-
tients is similar to that reported recently by other authors
[14]. Cumulatively, these findings suggest that marketing
of extended-release DAs contributes significantly to modi-
fying therapeutic strategies for early PD patients referred
to our institution. Indirectly, these changes allowed stric-
ter adherence to the current therapeutic guidelines for un-
complicated PD [1] and are in accord with a recent report
from France [15].
Our results show increased prescription of DAs in 2011
compared to 2007 in most subgroups (Tables 2 and 3). In
particular, it is of interest that a significant increase in
monotherapy with DAs, coupled with significantly re-
duced monotherapy with LD, was found in patients be-
tween 65 and 75 years of age (Table 2). Within this age
group, DAs were prescribed (as monotherapy or in com-
bination with LD) in more than 90% of cases in 2011 com-
pared to 62% of cases in 2007. We think the increased use
of DAs and the reduction in LD therapy occurred in this
group of patients, and not in younger patients, because
younger patients were already receiving higher dosages ofDAs. These findings suggest that extended-release for-
mulations of DAs may contribute significantly to delay-
ing LD prescriptions and/or to reducing daily LD
dosages for patients older than 70 years of age as well. If
confirmed by further studies with larger cohorts, these
results may suggest consideration of monotherapy with
DAs or combined DA-LD therapy as the preferred ap-
proach to treatment of patients with uncomplicated PD
younger than 75 years of age.
A further relevant observation of the present study is
related to the analysis of subgroups identified according
to functional requirements (Table 3). In subjects with
moderate functional requirements, significant increases
of monotherapy with DAs and significant reductions of
monotherapy with LD were found in 2011 compared to
2007. Similar trends were observed in patients with high
functional requirements, although among the latter co-
hort, significance was reached for monotherapy with
only DAs. In particular, in this latter subgroup, the most
frequently prescribed therapy was combined LD and DA
in 2007 (50% of cases) and monotherapy with DAs in
2011 (59% of cases).
Moreover, it is interesting to note that there was a
discrete relationship between the results in the age-related
and functional requirement–related subgroups. We think
this latter finding probably reflects more requests for im-
proved function among younger patients. In this respect,
it is notable that the significantly increased prescription of
monotherapy with DAs in patients carrying out daily pro-
fessional and/or personal activities may be related to the
higher daily doses of extended-release DAs in 2011 com-
pared to immediate-release formulations in 2007 (Table 3).
In turn, this may reflect higher tolerability (that is, reduced
peak-dose side effects) of extended-release formulations
than immediate-release DAs [8-10].Conclusions
The results of the present study suggest that extended-
release DAs can be substituted for immediate-release
DAs with less side effects and can contribute to sparing
use of LD. These findings are in line with the results of
previous randomized trials of extended-release DAs
[7-9] in patients with uncomplicated PD. Moreover,
the introduction of extended-release DAs may contrib-
ute to widening the prescription of these drugs as
monotherapy or in combination with LD for patients
older than 70 years of age and still engaged in intense
or regular daily activities. Further studies using more
detailed methodologies with larger sample sizes are
needed to confirm these preliminary findings, as well
as to investigate the post-marketing role of extended
extended-release DAs in patients with more advanced
stages of PD.
Pellicano et al. European Journal of Medical Research 2013, 18:60 Page 6 of 6
http://www.eurjmedres.com/content/18/1/60Abbreviations
DA: Dopamine agonist; H&Y: Hoehn and Yahr; LD: Levodopa; PD: Parkinson’s
disease; PP: Pramipexole; RP: Ropinirole; RT: Rotigotine; UPDRS-III: Unified
Parkinson’s Disease Rating Scale part III.
Competing interests
The authors declare that they have no conflicts of interest.
Authors’ contributions
CP conceived the study, participated in its design, collected data and wrote
the first draft of the manuscript. DB, AF and PL participated in the design of
the study, collected data and critically reviewed the first draft of the
manuscript. MG participated in the design of the study, performed the
statistical analysis and critically reviewed the first draft of the manuscript. FEP
conceived the study, participated in the study design and coordination and
critically reviewed the first draft of the manuscript. All authors read and
approved the final manuscript.
Acknowledgments
This study was by grants from Ministry of Education, University and Research
(MIUR) (to FEP).
Author details
1Department of Neuroscience, Mental Health and Sensory Organs –
(NESMOS), Sapienza University, Via di Grottarossa, 1035-00189, Rome, Italy.
2Movement Disorder Unit, Sant’Andrea Hospital, Via di Grottarossa,
1035-00189, Rome, Italy. 3Scientific Institute for Research, Hospitalization and
Health Care (IRCSS), Fondazione Santa Lucia, Via Ardeatina, 306-00179, Rome,
Italy.
Received: 21 July 2013 Accepted: 6 December 2013
Published: 21 December 2013
References
1. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen
JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C, European Federation of
Neurological Societies; Movement Disorder Society–European Section: Review
of the therapeutic management of Parkinson’s disease. Report of a joint
task force of the European Federation of Neurological Societies and the
Movement Disorder Society–European Section. Part 1: early
(uncomplicated) Parkinson’s disease. Eur J Neurol 2006, 13:1170–1185.
2. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and
pharmacodynamic properties of drugs used in the treatment of
Parkinson’s disease. Clin Pharmacokinet 2002, 41:261–309.
3. Bonuccelli U, Del Dotto P, Rascol O: Role of dopamine receptor agonists
in the treatment of early Parkinson’s disease. Parkinsonism Relat Disord
2009, 15(Suppl 4):S44–S53.
4. Bonuccelli U, Ceravolo R: The safety of dopamine agonists in the
treatment of Parkinson’s disease. Expert Opin Drug Saf 2008, 7:111–127.
5. Stocchi F: Continuous dopaminergic stimulation and novel formulations
of dopamine agonists. J Neurol 2011, 258(Suppl 2):S316–S322.
6. Giladi N, Boroojerdi B, Korczy AD, Burn DJ, Clarke CE, Schapira AHV, SP513
Investigators: Rotigotine transdermal patch in early Parkinson’s disease: a
randomized, double-blind, controlled study versus placebo and
ropinirole. Mov Disord 2007, 22:2398–2404.
7. Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L,
Juhel N, Schapira AH, Pramipexole ER Studies Group: Extended-release
pramipexole in early Parkinson disease: a 33-week randomized
controlled trial. Neurology 2011, 77:759–766.
8. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease-PD Monotherapy
Study Investigators: Ropinirole 24-hour prolonged release and ropinirole
immediate release in early Parkinson’s disease: a randomized, double-blind,
non-inferiority crossover study. Curr Med Res Opin 2008, 24:2883–2895.
9. Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B: Treatment of
patients with early and advanced Parkinson’s disease with rotigotine
transdermal system: age-relationship to safety and tolerability.
Parkinsonism Relat Disord 2013, 19:37–42.
10. Grosset D, European PD Therapy Compliance Study Group: Therapy
adherence issues in Parkinson’s disease. J Neurol Sci 2010, 289:115–118.
11. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson’s disease.
Arch Neurol 1999, 56:33–39.12. Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP, LeWitt P,
Oertel W, Quinn N, Sethi K, Stocchi F: Identification of motor and
nonmotor wearing-off in Parkinson’s disease: comparison of a patient
questionnaire versus a clinician assessment. Mov Disord 2005, 20:726–733.
13. Goetz CG, Blasucci L, Stebbins GT: Switching dopamine agonists in
advanced Parkinson’s disease: Is rapid titration preferable to slow?
Neurology 1999, 52:1227–1229.
14. Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T,
Sarashina A, Rascol O, Schapira AH, Barone P, Hauser RA, Poewe W,
Pramipexole ER Study Group: Efficacy and safety of extended- versus
immediate-release pramipexole in Japanese patients with advanced and
L-dopa-undertreated Parkinson disease: a double-blind, randomized trial.
Clin Neuropharmacol 2012, 35:174–181.
15. Fayard C, Bonaventure A, Benatru I, Roze E, Dumurgier J, Moisan F, Soumaré A,
Houssinot J, Dupupet JL, Mazurie JL, Balaboi I, Houeto JL, Krim E, Ranoux D,
Goldberg M, Imbernon E, Moreau T, Giroud M, Tzourio C, Elbaz A: Impact of
recommendations on the initial therapy of Parkinson’s disease: a population-
based study in France. Parkinsonism Relat Disord 2011, 17:543–546.
doi:10.1186/2047-783X-18-60
Cite this article as: Pellicano et al.: The impact of extended release
dopamine agonists on prescribing patterns for therapy of early
Parkinson’s disease: an observational study. European Journal of Medical
Research 2013 18:60.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
